NFKB1 and diffuse large B-cell lymphoma: In addition, considering the significant impact of immune response on DLBCL ABC and GCB, NFκB1 was selected as the drug target to be inhibited, thereby reducing the ability of both suppressing immune response by CD274 and promoting cell cycle and proliferation by CCND1.